ERAS logo

Erasca Inc (ERAS)

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatme...

NASDAQHealthcareBiotechnologyUSA

Company Profile

Stock Code
ERAS
ISIN Code
US29479A1088
Currency
US Dollar (USD)
IPO Date
2021-07-16

Contact Information

Company Address
3115 Merryfield Row, San Diego, CA, United States, 92121
Contact Phone
858 465 6511
Company Website
https://www.erasca.com
Fiscal Year End
December

Financial Highlights

Market Capitalization
$999,999.99
Gross Profit (TTM)
$0
Return on Assets (TTM)
-21.39%
EBITDA
$-999,999.99
Revenue (TTM)
$0